July 17th 2024
Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Pembrolizumab/Axitinib Combo Receives Priority Review From FDA for Frontline RCC
February 15th 2019A supplemental biologics license application for the combination of pembrolizumab and axitinib has received a priority review designation from the FDA as a frontline treatment for patients with advanced renal cell carcinoma, primarily based on data from the phase III KEYNOTE-426 study.
Read More
Updated Findings Show Sustained OS Benefit With Nivolumab/Ipilimumab Combo in Frontline RCC
February 14th 2019In updated 30-month follow-up data from the phase III CheckMate-214 trial, nivolumab combined with low-dose ipilimumab sustained strong responses and a survival benefit as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Read More
Hormonal Agents Lead to Improved Outcomes in African Americans With Chemo-Naive mCRPC
February 12th 2019Although African-American men are at a higher risk for metastatic castration-resistant prostate cancer and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.
Read More
Promising Findings Seen With LuPSMA in Heavily Pretreated mCRPC
February 12th 2019Treatment with the novel targeted radiation therapy lutetium-177 PSMA-617 demonstrated strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, according to phase II findings to be presented at the 2019 Genitourinary Cancers Symposium.
Read More
Apalutamide Trial Hits Primary Endpoints in Metastatic Castration-Sensitive Prostate Cancer
February 1st 2019In topline findings from the phase III TITAN trial announced today by Janssen, apalutamide in combination with androgen deprivation therapy significantly improved radiographic progression-free survival and overall survival versus placebo in patients with metastatic castration-sensitive prostate cancer.
Read More
Cancer Death Rates on the Decline, 2019 Cancer Stats Report Shows
January 10th 2019Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.
Read More
FDA Advances the Use of Metastasis-Free Survival as an Endpoint in nmCRPC
January 10th 2019In November 2018, the FDA issued a draft guidance recommending metastasis-free survival as an endpoint in drug trials for nonmetastatic castration-resistant prostate cancer, suggesting a major change in expectations for treatment of this tumor type.
Read More
The Future of Prostate Cancer Care: Taking the Fight Early
January 2nd 2019The future of prostate cancer treatment will involve using biomarkers to identify which patients will respond to which medications and applying regimens currently in use for patients with advanced disease to men with earlier-stage disease, said Howard I. Scher, MD.
Read More
For Prostate Cancer, Challenges Continue Over Finding Actionable Mutations
December 25th 2018Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The hard part, Sanjeev Kaul, MD, said at the 2018 Large Urology Group Practice Association Annual Meeting, is separating the mutations that are relevant from those that are not.
Read More
New Radiation Therapy Guidelines for Prostate Cancer Lowers Treatment Burden and Cost
November 30th 2018For clinicians who treat men with early-stage prostate cancer in their clinical practice, a new clinical guideline on the use of external beam radiation therapy has been developed by a panel of experts representing the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Urological Association.
Read More